[CAS NO. 1624602-30-7] VR23
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1624602-30-7]
Store
Catalog
SLK-S7933
Brand
Selleck
CAS
1624602-30-7
DESCRIPTION [1624602-30-7]
Overview
| MDL | MFCD28502093 |
|---|---|
| Molecular Weight | 477.88 |
| Molecular Formula | C19H16ClN5O6S |
| SMILES | O=S(N1CCN(C2=CC=NC3=CC(Cl)=CC=C23)CC1)(C4=CC=C([N+]([O-])=O)C=C4[N+]([O-])=O)=O |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0926 mL | 10.4629 mL | 20.9258 mL |
| 5 mM | 0.4185 mL | 2.0926 mL | 4.1852 mL |
| 10 mM | 0.2093 mL | 1.0463 mL | 2.0926 mL |
| 50 mM | 0.0419 mL | 0.2093 mL | 0.4185 mL |
Description
VR23 is a potent inhibitor with of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.
Targets
In vitro
In HeLa cells, VR23 induces ubiquitinated proteins accumulation. In RPMI 8226 and KAS 6 cells, VR23 inhibits cell growth with IC50 of 2.94 and 1.46 μM, respectively. VR23 is also equally effective on both bortezomib (BTZ)-sensitive and -resistant RPMI 8226 and ANBL6 cells cells. When used in combination of bortezomib in the cells above, VR23 shows synergistic effects on cell growth inhibition. In addition, VR23 selectively induces cancer cell apoptosis by causing the accumulation of ubiquitinated cyclin E.
In vivo
In ATH490 athymic mice engrafted with MDA-MB-231 metastatic breast cancer cells, VR23 (30mg/kg, i.p.) shows effective antitumor and antiangiogenic activities. VR23 also reduces adverse effects caused by paclitaxel in mice.
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.